(Q46607603)

English

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma

scientific article published in August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

1 reference

based on heuristic

inferred from title

Reginald F. Munden

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Frank V Fossella

3

object named as

Frank V Fossella

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

author name string

Edward S Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Merrill S Kies

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Bonnie S Glisson

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Sara Zaknoen

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Paul Statkevich

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Carmen Summey

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Katherine M W Pisters

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Vali Papadimitrakopoulou

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Mourad Tighiouart

11

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Andre Rogatko

12

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Fadlo R Khuri

13

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

language of work or name

0 references

publication date

1 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

104

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

561-569

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyltransferase inhibitors: a promising future in cancer treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21188

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21188

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16028213

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46607603&oldid=2121758991"